In This Section

Yang Ding, MD
Yang Ding, MD
Attending Physician

Dr. Ding is an attending physician with the Cancer Center at CHOP. As for her research, she works to discover oncogenic co-dependencies using genomics data with the goal to develop novel precision medicine techniques for children with cancer. She focuses on high-risk leukemias and computational biology.



Subscribe to be notified of changes or updates to this page.

Education and Training

BS, Yale University (Molecular, Cellular and Developmental Biology)

MD, Perelman School of Medicine, University of Pennsylvania

Internship, Children's Hospital of Philadelphia (Pediatrics)

Residency, Children's Hospital of Philadelphia (Pediatrics)

Fellowship, Children's Hospital of Philadelphia (Pediatric Hematology/Oncology)

Titles and Academic Titles

Attending Physician


Professional Memberships

American Academy of Pediatrics, 2012-

Children’s Oncology Group, 2016-

American Association for Cancer Research, 2017-

American Society of Hematology, 2018-

Professional Awards

K08 (NIH/NCI) Mentored Clinical Scientist Research Career Development Award, 2022-2027

Alex’s Lemonade Stand Foundation Young Investigator Grant Award, 2021-2024

Resource/Data Sharing Award, Alex’s Lemonade Stand Foundation with Northwestern Mutual, 2020

American Association for Cancer Research 2020 Annual meeting poster presentation, 2020

Abramson Cancer Center Paul Calabresi Career Development Award for Clinical Oncology K12, 2019-2021

CHOP Research Institute Poster Day Basic Science Prize Award and Symposium invited speaker, 2019

American Society of Hematology-European Hematology Association Translational Research Training in Hematology (TRTH) Awardee, 2019

American Association for Cancer Research “Molecular Biology in Clinical Oncology” workshop selection, Snowmass, CO, 2017

Alex’s Lemonade Stand Foundation Pediatric Oncology Student Training Grant, 2011

Publication Highlights

He B, Gao P, Ding Y, Chen C, Chen GM, Chen C, Kim H, Tasian SK, Hunger SP, Tan K. Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. Science Advances. 2020 Jul; 6(30):eaba3064. PMID: 32832663 PMCID: PMC7439310
Chen GM, Azzam A, Ding YY, Barrett DM, Grupp SA, Tan K. Dissecting the Tumor-Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. Clin Cancer Res. 2020 Jul; 26(14): 3505-3513. PMID: 32127393
Hu Y, Chen CH, Ding YY, Wen X, Wang B, Gao L, Tan K. Optimal control nodes in disease-perturbed networks as targets for combination therapy. Nat Commun. 2019 May; 10(1): 2180. PMID: 31097707
Taylor DM, Aronow BJ, Tan K, et al. The pediatric cell atlas: Defining the growth phase of human development at single-cell resolution. Dev Cel. 2019 Apr; 49(1):10-29. PMID: 30930166
Ding YY, Stern JW, Jubelirer TF, Wertheim GB, Li F, Chang F, Gu Z, Mullighan CG, Li Y, Harvey RC, Chen I-M, Willman CL, Hunger SP, Li MM, Tasian SK. Clinical Efficacy of Ruxolitinib and Chemotherapy in a Child with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia with GOLGA5-JAK2 Fusion and Induction Failure. Haematologica. 2018 Sep; 103(9):e427-e431, 2018. PMID: 29773603